| Literature DB >> 12890318 |
James J Sejvar1, A Arturo Leis, Dobrivoje S Stokic, Jay A Van Gerpen, Anthony A Marfin, Risa Webb, Maryam B Haddad, Bruce C Tierney, Sally A Slavinski, Jo Lynn Polk, Victor Dostrow, Michael Winkelmann, Lyle R Petersen.
Abstract
Acute weakness associated with West Nile virus (WNV) infection has previously been attributed to a peripheral demyelinating process (Guillain-Barré syndrome); however, the exact etiology of this acute flaccid paralysis has not been systematically assessed. To thoroughly describe the clinical, laboratory, and electrodiagnostic features of this paralysis syndrome, we evaluated acute flaccid paralysis that developed in seven patients in the setting of acute WNV infection, consecutively identified in four hospitals in St. Tammany Parish and New Orleans, Louisiana, and Jackson, Mississippi. All patients had acute onset of asymmetric weakness and areflexia but no sensory abnormalities. Clinical and electrodiagnostic data suggested the involvement of spinal anterior horn cells, resulting in a poliomyelitis-like syndrome. In areas in which transmission is occurring, WNV infection should be considered in patients with acute flaccid paralysis. Recognition that such weakness may be of spinal origin may prevent inappropriate treatment and diagnostic testing.Entities:
Mesh:
Year: 2003 PMID: 12890318 PMCID: PMC3023428 DOI: 10.3201/eid0907.030129
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Serologic results for West Nile virus (WNV)–specific antibodies in patients with acute flaccid paralysis associated with acute WNV infectiona
| IgM-capture enzyme immunoassay | Plaque reduction neutralization assay | ||||||
|---|---|---|---|---|---|---|---|
| Case | Onset | Collection | Sample | SLEV | WNV | SLEV | WNV |
| 1 | 6/24 | 7/12 | Serum | 3.5 | 22.3 | 320 | 5,120 |
|
|
|
|
|
|
|
|
|
| 2 | 7/12 | 7/16 | Serum | 8.0 | 22.7 | 80 | 1,280 |
|
|
|
|
|
|
|
|
|
| 3 | 7/26 | 8/1 | Serum | 2.79 | 24.9 | <10 | 640 |
|
|
|
|
|
|
|
|
|
| 4 | 7/29 | 8/3 | Serum | 1.1 | 14.1 | <10 | 80 |
| 4 | 7/29 | 8/3 | CSF | 3.3 | 39.2 |
|
|
| 4 | 7/29 | 8/13 | Serum | 4.4 | 23.5 | 40 | 2,560 |
|
|
|
|
|
|
|
|
|
| 5 | 8/11 | 8/15 | Serum |
| 2.02 |
|
|
| 5 | 8/11 | 8/29 | Serum | 3.4 | 25.7 |
|
|
|
|
|
|
|
|
|
|
|
| 6 | 8/13 | 8/16 | CSF | 6.1 | 23.8 |
|
|
| 6 | 8/13 | 8/16 | Serum | 1.0 | 5.7 | <10 | 40 |
|
|
|
|
|
|
|
|
|
| 7 | 9/1 | 10/24 | Serum | 2.8 | 10.6 | 10 | 320 |
| 7 | 9/1 | 9/6 | CSF | Not performed | 7.4 | ||
aIgM, immunoglobulin M; SLEV, Saint Louis encephalitis virus; CSF, cerebrospinal fluid.
Initial clinical signs and symptoms in patients with acute flaccid paralysis associated with acute West Nile virus infection
| Case no. | Fever
( | Headache | Nuchal rigidity | Altered mental status | Tremor | Distribution of weaknessa |
|---|---|---|---|---|---|---|
| 1 | + | + | + | + | + | Upper and lower limbs, R > L |
|
|
|
|
|
|
|
|
| 2 | + | + | - | + | - | Upper and lower limbs, R > L |
|
|
|
|
|
|
|
|
| 3 | + | - | - | - | + | Lower limbs, R > L |
|
|
|
|
|
|
|
|
| 4 | + | + | + | + | + | R upper limb |
|
|
|
|
|
|
|
|
| 5 | - | + | - | - | - | R upper limb |
|
|
|
|
|
|
|
|
| 6 | + | + | - | - | + | Lower limbs, R > L |
|
|
|
|
|
|
|
|
| 7 | + | + | + | - | - | Upper and lower limbs, L > R; bulbar muscles |
aR, right; L, left.
Initial laboratory findings in patients with acute flaccid paralysis associated with acute West Nile virus infectiona
| Case no. | Leukocytes (x103/mm3) | Hematocrit (%) | CSF WBC (/mm3) | CSF RBC (/mm3) | CSF protein (mg/dL) | CSF glucose (mg/dL) |
|---|---|---|---|---|---|---|
| 1 | 17.6 | 38.0 | 3 | 1,778 | 89 | 54 |
|
|
|
|
|
|
|
|
| 2 | 3.6 | 38.2 | 2,600 | 87 | 204 | 99 |
|
|
|
|
|
|
|
|
| 3 | 11.8 | 44.4 | 140 | 40 | 234 | 74 |
|
|
|
|
|
|
|
|
| 4 | 9.5 | 37.8 | 143 | 4 | 116 | 119 |
|
|
|
|
|
|
|
|
| 5 | 7.9 | 45.6 | Not performed | Not performed | Not performed | Not performed |
|
|
|
|
|
|
|
|
| 6 | 13.0 | 45.4 | 329 | 7 | 75 | 66 |
|
|
|
|
|
|
|
|
| 7 | 10.3 | Not performed | 182 | 9 | 37 | 79 |
aCSF, cerebrospinal fluid; WBC, leukocyte count; RBC, erythrocyte count.
Clinical characteristics of patients with West Nile virus–associated acute flaccid paralysis compared with patients with typical Guillain-Barré syndrome (25–27)a
| Characteristic | West Nile virus–associated flaccid paralysis | Guillain-Barré syndrome |
|---|---|---|
| Timing of onset | Acute phase of infection | 1–8 weeks after acute infection |
| Fever and leukocytosis | Present | Absent |
| Weakness distribution | Asymmetric; occasional monoplegia | Generally symmetric; proximal and distal muscles |
| Sensory symptoms | Absence of numbness, paresthesias, or sensory loss; occasional myalgias | Painful distal paresthesias and sensory loss |
| Bowel/bladder involvement | Often present | Rare |
| Concurrent encephalopathy | Often present | Absent |
| CSF profile | Pleocytosis and elevated protein | No pleocytosis; elevated protein (albuminocytologic dissociation) |
| Electrodiagnostic features | Anterior horn cell/motor axon: reduced/absent CMAPs, preserved SNAPs; asymmetric denervation | Demyelination: marked slowing of conduction velocity; conduction block, temporal dispersion; reduced SNAPs |
aCSF, cerebrospinal fluid; CMAPs, compound muscle action potentials; SNAPSs, sensory nerve action potentials.